Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H1 2016

$2,000

The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its …..

Total Pages: 124

Global Markets Direct’s, ‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2016’, provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
- The report reviews pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Hepatocellular Carcinoma (HCC) therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Hepatocellular Carcinoma (HCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Metastatic Hepatocellular Carcinoma (HCC) Overview 9
Therapeutics Development 10
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview 10
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis 11
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies 12
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes 14
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies 17
Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes 18
Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development 19
Acceleron Pharma, Inc. 19
AstraZeneca Plc 20
AVEO Pharmaceuticals, Inc. 21
Celgene Corporation 22
Eli Lilly and Company 23
F. Hoffmann-La Roche Ltd. 24
HanAll Biopharma Co., Ltd. 25
Incuron, LLC 26
Johnson & Johnson 27
Mirna Therapeutics, Inc. 28
Molecular Partners AG 29
MolMed S.p.A. 30
Novartis AG 31
OncoMed Pharmaceuticals, Inc. 32
Pfizer Inc. 33
PharmAbcine, Inc. 34
Verlyx Pharma Inc. 35
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
AV-203 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AZD-9150 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CC-122 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
codrituzumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
dalantercept - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
emibetuzumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
erdafitinib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
HL-143 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ipafricept - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
LY-3039478 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
LY-3127804 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
mepacrine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MP-0250 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MRX-34 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NGR-hTNF - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
OSU-2S - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
palbociclib - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
pasireotide - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pentamidine isethionate - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PF-04518600 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
sonidegib phosphate - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
temsirolimus - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TTAC-0001 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Metastatic Hepatocellular Carcinoma (HCC) - Recent Pipeline Updates 91
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects 119
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products 120
Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones 121
Featured News & Press Releases 121
Nov 20, 2014: ISIS-STAT3 Rx Data Presented by AstraZeneca at European Cancer Symposium 121
Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio 122
May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34 122
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 123
Disclaimer 124

List of Tables
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2016 10
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Acceleron Pharma, Inc., H1 2016 19
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca Plc, H1 2016 20
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 21
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Celgene Corporation, H1 2016 22
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eli Lilly and Company, H1 2016 23
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 24
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 25
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Incuron, LLC, H1 2016 26
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Johnson & Johnson, H1 2016 27
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H1 2016 28
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Molecular Partners AG, H1 2016 29
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MolMed S.p.A., H1 2016 30
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H1 2016 31
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 32
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Pfizer Inc., H1 2016 33
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by PharmAbcine, Inc., H1 2016 34
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Verlyx Pharma Inc., H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Number of Products by Stage and Target, H1 2016 38
Number of Products by Stage and Mechanism of Action, H1 2016 40
Number of Products by Stage and Route of Administration, H1 2016 42
Number of Products by Stage and Molecule Type, H1 2016 44
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Recent Pipeline Updates, H1 2016 91
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H1 2016 119
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H1 2016 120

List of Figures
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2016 10
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy Products, H1 2016 36
Number of Products by Top 10 Targets, H1 2016 37
Number of Products by Stage and Top 10 Targets, H1 2016 37
Number of Products by Top 10 Mechanism of Actions, H1 2016 39
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 39
Number of Products by Routes of Administration, H1 2016 41
Number of Products by Stage and Routes of Administration, H1 2016 41
Number of Products by Molecule Types, H1 2016 43
Number of Products by Stage and Molecule Types, H1 2016 43

Companies Mentioned

Acceleron Pharma, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
HanAll Biopharma Co., Ltd.
Incuron, LLC
Johnson & Johnson
Mirna Therapeutics, Inc.
Molecular Partners AG
MolMed S.p.A.
Novartis AG
OncoMed Pharmaceuticals, Inc.
Pfizer Inc.
PharmAbcine, Inc.
Verlyx Pharma Inc.


LICENSE TYPE